Compare AbbVie Inc (ABBV) vs Reddit Inc (RDDT) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Reddit (RDDT) trades at $200.67, up 3.13% today, reflecting strong momentum. The stock shows a bullish technical stance with moving averages aligned positively, though the RSI suggests potential overbought conditions. Fundamentally, the company exhibits robust revenue growth, with 2025 revenue at $2.2B and net income of $529.72M, supported by high gross margins of 91.37%. Recent earnings have mostly beaten expectations, and analyst sentiment is overwhelmingly positive with a consensus price target of $229.11. News highlights focus on AI safety initiatives and advertising growth.

The outlook for RDDT is favorable, driven by strong financial performance, expanding user engagement, and strategic AI investments. Key opportunities include sustained revenue growth and market share gains in social media. Risks involve competitive pressures, reliance on advertising revenue, and market volatility. With no sell ratings and solid cash flow generation, the stock presents a compelling case for growth-oriented investors, though valuation multiples remain elevated.